Lot-to-lot consistency of a tetravalent dengue vaccine in healthy adults in Australia: A randomised study

Vaccine

Volumn 33, Issue 39, 2015, Pages 5127-5134

  Torresi, Joseph ^a,b   Heron, Leon G ^c   Qiao, Ming ^d   Marjason, Joanne ^e   Chambonneau, Laurent ^f   Bouckenooghe, Alain ^g   Boaz, Mark ^f   van der Vliet, Diane ^f   Wallace, Derek ^g   Hutagalung, Yanee ^g   Nissen, Michael D ^h   Richmond, Peter C ⁱ  

^a AUSTIN HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^d ROYAL ADELAIDE HOSPITAL   (Australia)

^e Q Pharm Pty Ltd   (Australia)

^f SANOFI PASTEUR   (France)

^g Clinical Development   (Singapore)

^h ROYAL CHILDREN'S HOSPITAL   (Australia)

ⁱ UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Dengue; Flavivirus; Immunogenicity; Vaccine

Indexed keywords

DENGUE VACCINE; NEUTRALIZING ANTIBODY; PLACEBO; LIVE VACCINE; VIRUS ANTIBODY;

ADULT; ANTIBODY RESPONSE; ARTICLE; AUSTRALIA; CONTROLLED STUDY; DENGUE; DENGUE VIRUS 1; DENGUE VIRUS 2; DENGUE VIRUS 3; DENGUE VIRUS 4; DRUG SAFETY; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VACCINATION; ADOLESCENT; BLOOD; CLINICAL TRIAL; IMMUNOLOGY; MIDDLE AGED; NORMAL HUMAN; STANDARDS; SUBCUTANEOUS DRUG ADMINISTRATION; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; AUSTRALIA; DENGUE; DENGUE VACCINES; FEMALE; HEALTHY VOLUNTEERS; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PLACEBOS; VACCINES, ATTENUATED; YOUNG ADULT;

EID: 84941745078     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.08.008     Document Type: Article

References (30)

1. World Health Organization Global strategy for dengue prevention and control: 2012-2020 2012, WHO, Avilable from: 〈http://www.who.int/denguecontrol/9789241504034/en/〉 (accessed 5 July 2013).
2. Tatem A.J., Hay S.I., Rogers D.J. Global traffic and disease vector dispersal. Proc Natl Acad Sci USA 2006, 103:6242-6247.
3. Bhatt S., Gething P.W., Brady O.J., Messina J.P., Farlow A.W., Moyes C.L., et al. The global distribution and burden of dengue. Nature 2013, 496:504-507.
4. Gomez-Dantes H., Willoquet J.R. Dengue in the Americas: challenges for prevention and control. Cad Saude Publica 2009, 25(Suppl 1):S19-S31.
5. Tapia-Conyer R., Betancourt-Cravioto M., Mendez-Galvan J. Dengue: an escalating public health problem in Latin America. Paediatr Int Child Health 2012, 32(Suppl 1):14-17.
6. Gubler D.J. Dengue and dengue hemorrhagic fever. Clin Microbiol Rev 1998, 11:480-496.
7. Ratnam I., Black J., Leder K., Biggs B.A., Matchett E., Padiglione A., et al. Incidence and seroprevalence of dengue virus infections in Australian travellers to Asia. Eur J Clin Microbiol Infect Dis 2012, 31:1203-1210.
8. Freedman D.O., Weld L.H., Kozarsky P.E., Fisk T., Robins R., von Sonnenburg F., et al. Spectrum of disease and relation to place of exposure among ill returned travelers. N Engl J Med 2006, 354:119-130.
9. Leder K., Mutsch M., Schlagenhauf P., Luxemburger C., Torresi J. Seroepidemiology of dengue in travellers: a paired sera analysis. Travel Med Infect Dis 2013, 11:210-213.
10. Capeding R.Z., Luna I.A., Bomasang E., Lupisan S., Lang J., Forrat R., et al. Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines. Vaccine 2011, 29:3863-3872.
11. Sabchareon A., Wallace D., Sirivichayakul C., Limkittikul K., Chanthavanich P., Suvannadabba S., et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 2012, 380:1559-1567.
12. Poo J., Galan F., Forrat R., Zambrano B., Lang J., Dayan G.H. Live-attenuated tetravalent dengue vaccine in dengue-naive children, adolescents, and adults in Mexico City: randomized controlled phase 1 trial of safety and immunogenicity. Pediatr Infect Dis J 2011, 30:e9-e17.
13. Johnson C., Thakur M., Boaz M., Dayan G. Immunogenicity and safety of three formulations of a tetravalent dengue vaccine candidate among healthy adults in the US. Presented at: IDweek 2012 2012, Available from: 〈https://idsa.confex.com/idsa/2012/webprogram/Paper37442.html〉 (accessed 5 July 2013).
14. Morrison D., Legg T.J., Billings C.W., Forrat R., Yoksan S., Lang J. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. J Infect Dis 2010, 201:370-377.
15. Lanata C.F., Andrade T., Gil A.I., Terrones C., Valladolid O., Zambrano B., et al. Immunogenicity and safety of tetravalent dengue vaccine in 2-11 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura, Peru. Vaccine 2012, 30:5935-5941.
16. Leo Y.S., Wilder-Smith A., Archuleta S., Shek L.P., Chong C.Y., Leong H.N., et al. Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 y: phase II randomized controlled trial in Singapore. Hum Vaccin Immunother 2012, 8:1259-1271.
17. Tran N.H., Luong C.Q., Vu T.Q.H., Lang J., Vu Q.D., Bouckenooghe A., et al. Safety and immunogenicity of recombinant, live attenuated tetravalent dengue vaccine (CYD-TDV) in healthy Vietnamese adults and children. J Vaccines Vaccin 2012, 3:1000162.
18. Lang J. Development of Sanofi Pasteur tetravalent dengue vaccine. Rev Inst Med Trop Sao Paulo 2012, 54(Suppl 18):S15-S17.
19. Guy B., Barrere B., Malinowski C., Saville M., Teyssou R., Lang J. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine 2011, 29:7229-7241.
20. World Health Organization Clinical considerations for evaluation of vaccines for prequalification. Points to consider for manufacturers of human vaccines 2010, WHO, Available at: 〈http://www.who.int/immunization_standards/vaccine_quality/clinical_considerations_oct10.pdf〉 (accessed 13 April 2015).
21. Qiao M., Shaw D., Forrat R., Wartel-Tram A., Lang J. Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity, and safety of a tetravalent dengue vaccine in humans. Am J Trop Med Hyg 2011, 85:724-731.
22. Dayan G.H., Garbes P., Noriega F., Izoton de Sadovsky A.D., Rodrigues P.M., Giuberti C., et al. Immunogenicity and safety of a recombinant tetravalent dengue vaccine in children and adolescents ages 9-16 years in Brazil. Am J Trop Med Hyg 2013, 89:1058-1065.
23. Villar L.A., Rivera-Medina D.M., Arredondo-Garcia J.L., Boaz M., Starr-Spires L., Thakur M., et al. Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9-16 year olds: a randomized, controlled, phase II trial in Latin America. Pediatr Infect Dis J 2013, 32:1102-1109.
24. Roehrig J.T., Hombach J., Barrett A.D. Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses. Viral Immunol 2008, 21:123-132.
25. Timiryasova T.M., Bonaparte M.I., Luo P., Zedar R., Hu B.T., Hildreth S.W. Optimization and validation of a plaque reduction neutralization test for the detection of neutralizing antibodies to four serotypes of dengue virus used in support of dengue vaccine development. Am J Trop Med Hyg 2013, 88:962-970.
26. World Health Organization Guidelines for prevention and control of dengue and dengue haemorrhagic fever 1999, WHO, Available at: 〈http://www.themimu.info/sites/themimuinfo/files/documents/RefDoc_Health_WHO_Regional_Guidelines_on_Dengue_DHF_Prevention_Control.pdf〉 (Accessed 13 April 2015) (WHO Regional Office for South-East Asia, SEARO No. 29).
27. World Health Organization World Health Organization. Guidelines on the quality. safety and efficacy of dengue tetravalent vaccines (live, attenuated) 2011, WHO, Geneva, (WHO/BS/11.2159) Available at: 〈http://www.who.int/biologicals/BS2159_Dengue_WITH_LINE_NUMBERS_TRS_v47_18Jul2011_sub2.pdf〉 (accessed 20 October 2014).
28. World Health Organization Guidelines for plaque reduction neutralization testing of human antibodies to dengue viruses 2007, WHO, (WHO/IVB/07.07) Available at: 〈http://whqlibdoc.who.int/hq/2007/who_ivb_0707_eng.pdf〉 (accessed 20 October 2014).
29. Capeding M.R., Tran N.H., Hadinegoro S.R., Ismail H.I., Chotpitayasunondh T., Chua M.N., et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 2014, 384:1358-1365.
30. Villar L., Dayan G.H., Arredondo-Garcia J.L., Rivera D.M., Cunha R., Deseda C., et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med 2015, 372:113-123.